| Objective Several researches have shown that the probiotics play an important role in the prevention and treatment of intestinal tumors, but the molecular mechanism is still not clear. The purpose of this study is to investigate the effects of proliferation inhibition of C.butyricum culture supernatant(C.b.cs) on colon cancer SW-480 cells, and to explore the possible active ingredients and related molecular mechanism.Method The C.b.cs was conducted by C.butyricum anaerobic fermentation. After the treatment of C.b.cs, CCK-8 and FCM were used to test the cell proliferation and apoptosis. Furthermore, high efficiency liquid chromatography(HPLC) was used to analyze the concentrations of the main organic acid in C.b.cs. The expression of TLR4〠Cyclin D1 and NF-κB were detected by Western blot and q RT-PCR after the treatment of C.b.cs. Next, the SW-480 cells was treated with lipopolysaccharide(LPS) for 6 h, TLR4 expression was detected, and butyrate and C.b.cs were used to treat the cells after the stimulation of LPS, the expression of Cyclin D1 and NF-κB were detected.Results C.b.cs inhibits the proliferation of SW-480 cells in dose-dependent manner, which can also induce apoptosis and G0/G1 phase arrest. HPLC analysis showed that the concentrations of acetate and butyrate were 9.27mg/ml and 4.53mg/ml in C.b.cs respectively. The expression of TLR4 was inhibited after the treatment of C.b.cs and butyrate, as the downstream gene of TLR4, the expression of NF-κB and Cyclin D1 were also inhibited. Furtherly, LPS can activate TLR4 expression and promote SW-480 cells proliferation, and C.b.cs and butyrate attenuated the upregulation of TLR4 after the stimulation of LPS, and the expression of NF-κB and Cyclin D1 were also inhibited,cell proliferation was also inhibited.Conclusion C.b.cs inhibited the proliferation of SW-480 cells by downregulation the expression of TLR4/NF-κB pathway, and butyrate may be the active components in C.b.cs to inhibit the proliferation of SW-480 cells.Objectives Serum micro RNA-21(mi R-21) expression has been shown to be significantly up-regulated in breast cancer, which implies that it could be a biomarker to discriminate breast cancer patients from healthy controls. We therefore performed this meta-analysis to assess the diagnostic value of mi R-21 for breast cancer.Methods Relevant articles were collected from Pub Med, Scopus, Embase, the Cochrane Library, Bio Med Central, ISI Web of Knowledge, China National Knowledge Infrastructure(CNKI), Wan Fang Data and Technology of Chongqing(VIP) databases, from inception to June 10, 2014 by two independent researchers. Diagnostic capacity of mi R-21 for breast cancer was assessed using pooled sensitivity and specificity, diagnostic odds ratio(DOR), area under the summary receiver operating characteristic(AUC) and Fagan’s nomogram. Meta-Disc software and STATA 12.0 were used to investigate the source of heterogeneity and to perform the meta-analysis.Results We used 6 studies with a total of 438 patients, and 228 healthy controls in this meta-analysis. The pooled sensitivity, specificity and DOR were 0.79(95% confidence interval[CI] 0.66-0.87), 0.85(95% CI 0.75-0.91), and 19.46(95% CI 8.74-43.30), respectively; positive and negative likelihood ratios were 5 and 0.25, and AUC was 0.89(95% CI 0.86-0.91). In addition, heterogeneity was clearly apparent but was not caused by the threshold effect.Conclusions This meta-analysis suggests that mi R-21 is a potential biomarker for early diagnosis of breast cancer with high sensitivity and specificity, its clinical application warrants further investigation. |
